Isofol Receives Positive Feedback From PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer |
| October 18, 2019 | October 2019 Bond Updates |
|
GOTHENBURG, Sweden, Oct. 18, 2019 /PRNewswire/ -- Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the successful completion of Japan's Pharmaceutical and Medical Devices Agency (PMDA) review of the Clinical Trial Notification (CTN), allowing the start of... |
| View more at: https://www.prnewswire.com:443/news-releases/isofol-receives-positive-feedback-from-pmda-in-japan-expanding-ongoing-global-pivotal-phase-3-agent-trial-in-first-line-metastatic-colorectal-cancer-300941095.html |
| Related News |